NO PRODUCT DISCUSSED: payments to doctors
Payments that named NO PRODUCT DISCUSSED as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $5.8M
- Providers
- 2,322
- Transactions
- 4,918
- Average per transaction
- $1,185
The per-transaction average — $1,185 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 2,322 providers the average total is $2,509, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sanofi | $2,671,588 | 45.9% |
| Sanofi-aventis U.S. LLC | $1,624,453 | 27.9% |
| Sanofi US Services Inc. | $818,641 | 14.1% |
| Sanofi Pasteur Inc. | $513,663 | 8.8% |
| Bioverativ Therapeutics Inc. | $189,336 | 3.2% |
| Omnilife Science, Inc | $8,750 | 0.2% |
| Vaxserve Inc. | $25 | 0.0% |